CD70-targeted immunoPET Imaging of Malignant Cancers

Launched by RENJI HOSPITAL · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new imaging method called CD70-targeted immunoPET/CT, which aims to help doctors spot certain types of cancers, including renal cancer (specifically clear cell renal cell carcinoma), various types of lymphoma, and nasopharyngeal carcinoma. The goal is to improve the way these cancers are diagnosed by understanding how this new imaging method works in the body.

To participate in this study, individuals should be between 18 and 80 years old, have a confirmed or suspected diagnosis of one of the cancers mentioned, and be able to provide informed consent. This means they need to understand and agree to the study's requirements. However, people who are pregnant, have severe liver or kidney problems, or are allergic to specific medical substances used in the imaging will not be eligible. Participants can expect to undergo imaging tests during the study, which will help researchers learn more about the effectiveness of this new diagnostic tool.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18-80 year-old and of either sex；
• • Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging;
• • Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.
• Exclusion Criteria:
• • Pregnancy；
• • Severe hepatic and renal insufficiency;
• • Allergic to single-domain antibody radiopharmaceuticals.